Home > Compound List > Product Information
Drospirenone_Molecular_structure_CAS_67392-87-4)
Click picture or here to close

Drospirenone

Catalog No. DB01395 Name DrugBank
CAS Number 67392-87-4 Website http://www.ualberta.ca/
M. F. C24H30O3 Telephone (780) 492-3111
M. W. 366.4932 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 1206

SYNONYMS

IUPAC name
(1R,2R,4R,10R,11S,14S,15S,16S,18S,19S)-10,14-dimethylspiro[hexacyclo[9.8.0.0^{2,4}.0^{5,10}.0^{14,19}.0^{16,18}]nonadecane-15,2'-oxolan]-5-ene-5',7-dione
IUPAC Traditional name
drospirenone
Synonyms
Drospirenonum [inn-latin]
DRSP
Drospirenona [inn-spanish]
6β,7β,15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17 carbolactone

DATABASE IDS

PubChem CID 68873
CAS Number 67392-87-4
PubChem SID 46507653

PROPERTIES

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Drospirenone is a synthetic progestin that is an analog to spironolactone. It is found in a number of birth control formulations. Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic.
Indication For the prevention of pregnancy in women who elect an oral contraceptive.
Pharmacology Drospirenone differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic.
Affected Organisms
Humans and other mammals
Biotransformation Extensively metabolized following oral or intravenous administration. The two major metabolites are inactive and are formed independent of the CYP450 enzyme system. The metabolites are the acid form of drospirenone formed by opening of the lactone ring and the 4,5-dihydro-drospirenone-3-sulfate.
Absorption Oral bioavailability is approximately 76%.
Half Life 30 hours
Protein Binding 97%
References
Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38. [Pubmed]
External Links
Wikipedia

REFERENCES

  • Krattenmacher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000 Jul;62(1):29-38. Pubmed